Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans…
M. Sonay Gürgen, chairman of the board and general manager of Selçuk Ecza Deposu, Turkey’s largest pharma distributory, offers his insider take on the pharmaceutical value chain in Turkey, the…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist…
Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry…
Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces…
Dr Orhan Mutlu Topal, general manager at Emre Ecza Ilac, offers an insider take on the Turkish vaccine industry, the challenges on the horizon for the Turkish pharmaceutical sector, and the…
Cem Kolak, founder and managing director of BL Turkey, the only Turkish Third Party Logistics (3PL) firm 100 percent dedicated to the biopharmaceutical and life sciences sectors, leverages his pioneering…
Meri Istiroti, group coordinator of Liv Hospital Group, shares the hospital’s success story since its beginning in 2013 to becoming a leading private healthcare institution dedicated to service, quality, and…
Emin Çakmak, chairman of the Turkish Healthcare Travel Council, offers deep insights into the healthcare travel industry and how it stretches beyond the commonly used term of “medical tourism”. Çakmak…
Elif Çelik, executive vice president of the Healthcare Division of Eczacıbaşı Group, explains the rationale behind the group’s divestment of its generics arm and its new strategy to establish itself…
Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the…
See our Cookie Privacy Policy Here